BridgeMD
New treatment option for Severe Aplastic Anemia
Official title Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
ClinicalTrials.gov ID: NCT06378060
What this study is testing
What is Modified transplantation system?
Modified transplantation system is an investigational medicine, being studied as a potential treatment for severe aplastic anemia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 3 to 65. Healthy volunteers may be eligible.
You may be able to join if
- Patients with benign or malignant hematological diseases such as leukemia, lymphoma, thalassemia, aplastic anemia, etc. diagnosed by NCCN guidelines...
- Age 3-65 years old;
- Weight 10Kg-100Kg;
- Eastern Cooperative Oncology Group (ECOG) score ≤3;
- No major organ injury (ECG ejection fraction \>45%; bilirubin \< 2 times the upper limit of normal value; AST and ALT \< 3 times the upper limit of...
You likely can't join if
- patients with nonhematologic diseases who are not eligible for transplantation or who do not wish to receive transplantation;
- patients with an expected survival of less than 1 month;
- patients with previous autologous or allogeneic hematopoietic stem cell transplantation;
- pregnant patients;
- patients with severe mental or neurological disorders that would affect the ability to provide informed consent and/or to report or observe adverse...
- other conditions that the investigator determines to be inappropriate for enrollment.
See the full eligibility criteria
- Patients with benign or malignant hematological diseases such as leukemia, lymphoma, thalassemia, aplastic anemia, etc. diagnosed by NCCN guidelines, and requiring allogeneic hematopoietic stem cell transplantation as...
- Age 3-65 years old;
- Weight 10Kg-100Kg;
- Eastern Cooperative Oncology Group (ECOG) score ≤3;
- No major organ injury (ECG ejection fraction \>45%; bilirubin \< 2 times the upper limit of normal value; AST and ALT \< 3 times the upper limit of normal value; serum creatinine \< 2 times the upper limit of normal...
- No severe infection;
- people voluntarily participated in this clinical trial and signed the informed consent.
- patients with nonhematologic diseases who are not eligible for transplantation or who do not wish to receive transplantation;
- patients with an expected survival of less than 1 month;
- patients with previous autologous or allogeneic hematopoietic stem cell transplantation;
- pregnant patients;
- patients with severe mental or neurological disorders that would affect the ability to provide informed consent and/or to report or observe adverse events;
- other conditions that the investigator determines to be inappropriate for enrollment.
The study team makes the final eligibility decision.
Where it's taking place
- Kunming, Yunnan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 3 years to 65 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kunming, Yunnan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.